About cookies on this site Our websites require some cookies to function properly (required). In addition, other cookies may be used with your consent to analyze site usage, improve the user experience and for advertising. For more information, please review your options. By visiting our website, you agree to our processing of information as described in IBM’sprivacy statement. To provide a smooth navigation, your cookie preferences will be shared across the IBM web domains listed here.
Publication
RecSys 2024
Workshop paper
Design and Assessment of Representative Hybrid Clinical Trials using Health Recommender System
Abstract
Incorporating real-world data (RWD) into clinical trials can enhance trial efficiency, diversity, and generalizability. This paper introduces the Framework for Research in Synthetic Control Arms (FRESCA), which uses a novel Recommender System combined with Equity Adjustment strategies to design and evaluate Representative Hybrid Clinical Trials (HCTs). FRESCA employs a novel matching algorithm through its recommendation system to select suitable patients from RWD while ensuring that the selected population is representative of the target demographic. This dual approach improves both patient selection and trial outcomes by balancing statistical appropriateness and equity. Simulations based on data from two existing randomized clinical trials (RCTs) show that using FRESCA to recommend patients from RWD and apply equity adjustments enhances internal validity and generalizability. Our analysis indicates that combining matching and equity adjustments yields more accurate treatment effect estimates and fair population representation, even with reduced RCT control group sizes. In contrast, using either method alone may result in biased outcomes. The flexibility of FRESCA to simulate various HCT scenarios makes it a valuable tool for advancing equitable and efficient clinical trial designs.